ANX-201 Combination Therapy Demonstrates Synergistic Inhibition of HIV-1 in Preclinical Tests
July 23 2007 - 6:00AM
PR Newswire (US)
ADVENTRX Presents Results at 4th Annual International AIDS Society
Conference SAN DIEGO, July 23 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals Inc. (AMEX:ANX), a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases,
announced today that it presented results demonstrating synergistic
HIV inhibitory activity of the Company's broad spectrum antiviral
drug candidate, ANX-201, when combined with approved nucleoside and
nucleotide reverse transcriptase inhibitors (N(t)RTI) in
preclinical tests. The results were presented at the 4th Annual
International AIDS Society (IAS) Conference on HIV Pathogenesis,
Treatment and Prevention in Sydney, Australia on July 23, 2007. The
poster entitled "Synergistic Antiretroviral Activity of
Pyrophosphate Analogue ANX-201 Paired with Nucleoside Reverse
Transcriptase Inhibitors In Vitro" was presented by Shani Waninger,
Ph.D., associate director for research and development for
ADVENTRX. "These preclinical results suggest that ANX-201 and
commonly prescribed N(t)RTIs represent a promising combination in
multidrug antiretroviral therapy," said Evan M. Levine, ADVENTRX's
chief executive officer. "Although ANX-201 and N(t)RTIs target the
same viral enzyme, ANX-201 exerts antiviral activity by a unique
mechanism and represents a novel class of reverse transcriptase
inhibitor. These data suggest that ANX-201 in combination with
N(t)RTIs has potential clinical advantages for HIV patients,
including enhanced viral suppression and slowed progression of drug
resistance. We are excited about these results and expect to
initiate a clinical trial with ANX-201 as a component of multi-drug
therapy for the treatment of HIV later this year." ANX-201 combined
at fixed ratios with N(t)RTIs including zidovudine, tenofovir,
abacavir, lamivudine, emtricitabine and stavudine resulted in
synergistic to additive inhibition of HIV-1 in cultured human cells
using standard in vitro assays. Furthermore, this synergistic
activity suggests that the addition of ANX-201 to a drug regimen
containing N(t)RTIs may have clinical advantages that include
enhanced antiviral activity and the potential for reduced toxicity.
A copy of the poster presentation is available for download from
the "Resources" section of the Company's web site at
http://www.adventrx.com/ under "Publications". About ANX-201
ANX-201 (thiophosphonoformic acid) is a pyrophosphate analog and
member of a new class of reverse transcriptase inhibitor (RTI) for
treatment of resistant HIV patients. ANX-201 has shown activity
against HIV drug-resistant clinical isolates in preclinical
studies. The resistance profile of ANX-201 is unique among approved
RTIs and has been shown to resensitize NRTI-resistant virus. In
preclinical studies, ANX-201 has shown broad-spectrum antiviral
activity against HIV-1, HIV-2, human and avian influenza viruses,
and herpes simplex viruses 1 and 2 (HSV-1 and HSV-2). ADVENTRX
plans to initiate a Phase 1/2 clinical trial of ANX-201 as a
component of multi-drug therapy for the treatment of HIV during
2007. About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a
biopharmaceutical research and development company focused on
commercializing proprietary product candidates for the treatment of
cancer and infectious diseases. The Company seeks to improve the
performance and safety of existing treatments by addressing
significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. More information can
be found on the Company's web site at http://www.adventrx.com/.
Forward Looking Statement ADVENTRX cautions you that statements
included in this press release that are not a description of
historical facts are forward-looking statements that involve risks
and assumptions that, if they materialize or do not prove to be
accurate, could cause ADVENTRX's results to differ materially from
historical results or those expressed or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to: the validity of research results; the risk
that preclinical results are not indicative of the success of
subsequent clinical trials and that products will not perform as
preclinical data suggests or as otherwise anticipated; unexpected
adverse side effects or inadequate therapeutic efficacy of ANX-201
and other uncertainties inherent in the drug development process;
the timing and success of clinical trials; difficulties or delays
in developing, testing, manufacturing, and obtaining regulatory
approval for ANX-201, including receiving necessary regulatory
approvals for a Phase 1/2 clinical trial of ANX-201; the risk that
ADVENTRX will be unable to raise sufficient capital to fund the
projects necessary to meet its anticipated or stated goals and
milestones, including funding the continued development of ANX-201
for the treatment of HIV or human or avian influenza; and other
risks and uncertainties more fully described in ADVENTRX's press
releases and public filings with the Securities and Exchange
Commission. ADVENTRX's public filings with the Securities and
Exchange Commission are available at http://www.sec.gov/. ADVENTRX
does not intend to update any forward-looking statement, including
as set forth in this press release, to reflect events or
circumstances arising after the date on which it was made.
DATASOURCE: ADVENTRX Pharmaceuticals Inc. CONTACT: Ioana C. Hone of
ADVENTRX Pharmaceuticals, +1-858-552-0866 Web site:
http://www.adventrx.com/
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024